Skip to Content

Neuromyelitis Optica (NMO) Spectrum Disorders: New Assay Offers Increased Sensitivity and Specificity

Early diagnosis and differentiation of Neuromyelitis optica (NMO) spectrum disorders are critically important to assure the most appropriate early treatment, making assays that are both highly sensitive and specific essential. Mayo Clinic studies, involving thousands of patients, have found the new cell-based aquaporin-4 (AQP4) antibody assay to be more sensitive and specific than enzyme-linked immunosorbent assay (ELISA) methods. The improved sensitivity and specificity of this test offered by Mayo Medical Laboratories will assist clinicians in distinguishing early stage NMO spectrum disorders from multiple sclerosis.

Watch the video below from Sean Pittock, M.D., to learn more about NMO and Mayo Medical Laboratories' new cell-based AQP4 antibody assay.



Brent Westra is a Marketing Segment Manager at Mayo Clinic Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.